FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
NPR News
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
(Image credit: Maddie Meyer)
Originally published by
NPR News
Aggregated from a public feed. Read the original at the source for the publisher's full presentation.
View original on npr.orgContinue reading
